Humoral and neutralising antibody responses to self-adjuvanting recombinant HCV virus like particles

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/520312

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Hepatitis C virus (HCV) infects 3% of the world's population and causes an estimated 476,000 deaths per year as a result of HCV associated end-stage liver disease. HCV is one of the most common notifiable infectious diseases in Australia with 16,000 new cases reported annually and a vaccine will reduce the number of new infections. The aim of this project is to develop HCV virus like particles (VLP's) that have the potential for future development of preventative vaccine against HCV.

Funded Activity Details

Start Date: 01-01-2008

End Date: 01-01-2011

Funding Scheme: NHMRC Postgraduate Scholarships

Funding Amount: $118,796.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Infectious Diseases

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

hepatitis C | humoral immunology | immune response | vaccine development | virus like particle

Related Links